Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
Autor: | Alessandra Ferlini, Maria Sofia Falzarano, Rachele Rossi, Fernanda Fortunato |
---|---|
Rok vydání: | 2021 |
Předmět: |
Duchenne muscular dystrophy
musculoskeletal diseases exon-skipping antisense oligonucleotide chemistry dystrophin restoration Genetic enhancement lcsh:Medicine Review Disease Bioinformatics Sarcomere 03 medical and health sciences 0302 clinical medicine medicine innovative clinical trials Muscular dystrophy 030304 developmental biology 0303 health sciences Sarcolemma biology stop codon reversion business.industry lcsh:R General Medicine medicine.disease gene therapy Exon skipping biology.protein Dystrophin business 030217 neurology & neurosurgery |
Zdroj: | Journal of Clinical Medicine, Vol 10, Iss 820, p 820 (2021) Journal of Clinical Medicine |
ISSN: | 2077-0383 |
DOI: | 10.3390/jcm10040820 |
Popis: | Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy affecting ~1:5000 live male births. Following the identification of pathogenic variations in the dystrophin gene in 1986, the underlining genotype/phenotype correlations emerged and the role of the dystrophin protein was elucidated in skeletal, smooth, and cardiac muscles, as well as in the brain. When the dystrophin protein is absent or quantitatively or qualitatively modified, the muscle cannot sustain the stress of repeated contractions. Dystrophin acts as a bridging and anchoring protein between the sarcomere and the sarcolemma, and its absence or reduction leads to severe muscle damage that eventually cannot be repaired, with its ultimate substitution by connective tissue and fat. The advances of an understanding of the molecular pathways affected in DMD have led to the development of many therapeutic strategies that tackle different aspects of disease etiopathogenesis, which have recently led to the first successful approved orphan drugs for this condition. The therapeutic advances in this field have progressed exponentially, with second-generation drugs now entering in clinical trials as gene therapy, potentially providing a further effective approach to the condition. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |